Executive functioning and quality of life in acromegaly.
acromegaly
cognition
executive function
growth hormone
Journal
Psychology research and behavior management
ISSN: 1179-1578
Titre abrégé: Psychol Res Behav Manag
Pays: New Zealand
ID NLM: 101514563
Informations de publication
Date de publication:
2019
2019
Historique:
entrez:
19
1
2019
pubmed:
19
1
2019
medline:
19
1
2019
Statut:
epublish
Résumé
Active acromegaly is a rare chronic endocrine disorder caused by excessive growth hormone (GH). Clinical studies suggest that cognitive performance is impaired in acromegaly - particularly executive function as well as short- and long-term memory. This study compared the quality of life (QoL) and executive functioning in acromegaly patients vs healthy controls. This was an observational case-control study on 38 subjects divided into 19 acromegaly patients and 19 matched controls. The groups were evaluated for QoL, attention, and executive function. All subjects completed Acromegaly Quality of Life Questionnaire (AcroQoL), Trail Making Test (parts A and B), Stroop, and phonemic fluency tests. Acromegaly patients had an AcroQoL global score that was significantly lower than controls. There were significant differences between the acromegaly group and the control group in terms of the physical effects ( Acromegaly patients display worse executive functioning than healthy controls and have a decreased QoL.
Identifiants
pubmed: 30655710
doi: 10.2147/PRBM.S183950
pii: prbm-12-039
pmc: PMC6322494
doi:
Types de publication
Journal Article
Langues
eng
Pagination
39-44Déclaration de conflit d'intérêts
Disclosure The authors report no conflicts of interest in this work.
Références
Front Neuroendocrinol. 2000 Oct;21(4):330-48
pubmed: 11013068
ScientificWorldJournal. 2006 Jan 18;6:53-80
pubmed: 16432628
Eur J Endocrinol. 2006 Aug;155(2):269-77
pubmed: 16868140
Endocrinol Metab Clin North Am. 2007 Mar;36(1):221-32
pubmed: 17336742
Nat Protoc. 2006;1(5):2277-81
pubmed: 17406468
Eur J Endocrinol. 2007 Oct;157(4):411-7
pubmed: 17893254
Eur J Endocrinol. 2008 Mar;158(3):305-10
pubmed: 18299462
Growth Horm IGF Res. 2009 Feb;19(1):24-30
pubmed: 18567522
Pituitary. 2009;12(3):177-85
pubmed: 18836838
Ann Behav Med. 2009 Apr;37(2):106-16
pubmed: 19455377
J Am Geriatr Soc. 2009 Aug;57(8):1441-6
pubmed: 19515112
J Clin Invest. 2009 Nov;119(11):3189-202
pubmed: 19884662
J Clin Endocrinol Metab. 2010 Sep;95(9):4367-79
pubmed: 20554710
J Clin Endocrinol Metab. 2010 Dec;95(12):E392-402
pubmed: 20843947
Exp Clin Endocrinol Diabetes. 2011 May;119(5):300-5
pubmed: 21031340
Neuropsychology. 2011 Sep;25(5):655-65
pubmed: 21574716
Pituitary. 2012 Sep;15(3):350-7
pubmed: 21735089
Intelligence. 2011 Jul;39(4):222-232
pubmed: 21789028
ISRN Endocrinol. 2011;2011:249421
pubmed: 22363870
Eur J Clin Invest. 2012 Dec;42(12):1317-24
pubmed: 23083406
PLoS One. 2013 Apr 04;8(4):e60041
pubmed: 23593161
Endocrine. 2014 Aug;46(3):585-93
pubmed: 24282035
Endocrine. 2014 Aug;46(3):365-7
pubmed: 24664361
Endocrine. 2015 Dec;50(3):523-5
pubmed: 26349939
J Pediatr Psychol. 2017 Jul 1;42(6):636-646
pubmed: 28008003
Endokrynol Pol. 2017;68(5):519-523
pubmed: 28879646
Endokrynol Pol. 2017;68(5):524-532
pubmed: 28879648
Pituitary. 2018 Jun;21(3):323-333
pubmed: 29644512
PLoS One. 2018 Apr 25;13(4):e0196329
pubmed: 29694417
Brain Res. 1993 Sep 10;621(2):260-6
pubmed: 8242339
Clin Endocrinol (Oxf). 1996 Mar;44(3):319-24
pubmed: 8729530